Items with tag "clinical trials"

News

Mithra Announces the Completion of its Lead Clinical Phase III Programme for Estelle

14 Nov 2018 - Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the completion of the Phase III Estelle® study in the US and Canada. Estelle® is Mit…

Read more

Argenx raised over $300 million in their US public offering

18 September 2018 - Read the press release here. Argenx is a Belgian clinical-stage biotechnology company, developing differentiated antibody-based therapies for the treatment of severe autoim…

Read more

Good News for Galapagos

Good News for Galapagos

It has been a huge month for Galapagos, with press releases issued in rapid succession. The news is all positive; the company has, in a very short amount of time, launched their initial public off…

Read more

GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial

Galapagos announces positive topline results with its autotaxin inhibitor GLPG1690 in patients with idiopathic pulmonary fibrosis (IPF) in the FLORA Phase 2a trial. Forced vital capacity (…

Read more

New drug for intestinal fibrosis

Researchers from Ghent University Hospital have forced a breakthrough in the fight against intestinal fibrosis, a complication that occurs especially in patients with Crohn's disease. Today, intes…

Read more

Celyad announces initiation of the SHRINK trial

SHRINK study to evaluate the synergetic effect of the concurrent administration of CYAD-01 (CAR-T NKG2D) with standard chemotherapy in patients suffering from metastatic colorectal cancer.

Read more

Galapagos' filgotinib enters non-infectious uveitis trial

The anti-inflammatory molecule enters yet another phase II trial.

Read more

Mithra Signs Deal with Fuji Pharma for Donesta in Asia

Mithra, a company specialized in Women’s Health, announces that it has signed an exclusive License and Supply Agreement (LSA) with Fuji Pharma, the leader in Women’s Health in Japan, for the comme…

Read more

Yet another phase 2 filgotinib study for Galapagos: cutaneous lupus erythematosus

Galapagos and development partner Gilead set out to explore filgotinib applicability even futher. This time, the molecule's anti-inflammatory capacity will be tested in cutaneous lupus erythematos…

Read more

argenx launches Phase II study for cutaneous T-cell lymphoma therapy

argenx starts a new phase II clinical trial with ARGX-110, a SIMPLE antibody targeting CD70. ARGX-110 will be evaluated as a monotherapy for relapsed/refractory cutaneous T-cell lymphoma (CTCL).

Read more

ASIT biotech's house dust mite rhinitis therapy achieves Phase I/IIa endpoint

Although ASIT's drug against house dust mite allergy has proven to be safe, little clinical efficacy has been detected.

Read more

Galapagos announces three new Phase 2 Proof-of-Concept studies with filgotinib

Galapagos, together with partner Gilead, sets out to expand the applicability of its flagship molecule Filgotinib. Three new phase II trials are initiated to assess the effect of Filgotinib in Sjö…

Read more

Kiadis Pediatric Investigation Plan concerning blood cancer approved by EMA

Kiadis Pharma N.V., a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that the Pedia…

Read more

TiGenix Announces Top-Line Phase I/II Results of AlloCSC-01 in Acute Myocardial Infarction

TiGenix, stem cell specialist focused on developing novel therapeutics from its two proprietary platforms of donor-derived expanded adipose derived stem cells (eASC) and donor-derived expanded car…

Read more

New Phase 2 studies with filgotinib in small bowel and fistulizing Crohn's disease

Galapagos NV announced two new Phase 2 studies investigating filgotinib in small bowel Crohn's disease as well as in fistulizing Crohn's disease. These studies are being led by filgotinib collabor…

Read more

Celyad obtains FDA approval to initiate the NKR-2 CAR-T cells THINK trial in the USA

Celyad announced that the U.S. FDA authorized the initiation of the THINK trial in the U.S. THINK evaluates NKR-2 CAR-T cells in seven indications, five solid cancers and two hematological maligna…

Read more

Cell therapy for Crohn's disease gets FDA boost to enter US market

TiGenix NV, an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platform of allogeneic stem cells, announced today that it has r…

Read more

Merck releases compelling data on Ablynx-developed psoriasis nanobody

Data from a phase Ib study reveal the Ablynx-developed bi-specific nanobody targeted against IL-17A/F as a promising new therapy to treat psoriasis. Patients in the highest dose group achieved 90%…

Read more

TiGenix Enrolls First Patient in Phase Ib/IIa Clinical Trial for Severe Sepsis

TiGenix, today announced that the first patient has been enrolled and treated in its Phase Ib/IIa clinical trial for Cx611 (SEPCELL) in the treatment of severe sepsis in community-acquired pneumon…

Read more

MERCK REPORTS ENCOURAGING RESULTS WITH ABLYNX' PSORIASIS NANOBODY

• Primary objective of safety and tolerability met • In the three highest dose groups, 100% of patients achieved a 75% or greater reduction in disease activity compared to 0% for placebo • The…

Read more

MITHRA PLANS TO SUBMIT MYRING FOR US AND EU APPROVAL IN Q2 2017

Following successful trials demonstrating bioequivalence to Nuvaring, Mithra Pharmaceuticals sets in motion the next steps to bring its Myring to the market.

Read more

ABLYNX INITIATES PHASE IIb STUDY OF INHALED ANTI-RSV NANOBODY

ALX-0171 is a first-in-class inhaled Nanobody® developed for the treatment of RSV infections. The drug was found to be safe and well tolerated in a Phase IIa study in hospitalized infants with a R…

Read more

argenx launches Phase II study of ARGX-113 for the treatment of myasthenia gravis

Llama antibody engineer argenx today announced the initiation of a Phase II proof-of-concept study of ARGX-113 in patients with myasthenia gravis (MG). "MG is a rare and debilitating muscle d…

Read more

Celyad Announces Registration of the first patient in the Belgian THINK trial

Celyad commences THINK trial with its cell-based CAR-T/NKR-2 immunotherapy 

Read more

Insights

argenx signs billion-dollar deal with Janssen

argenx signs billion-dollar deal with Janssen

Another Belgian biotech on the up and up: argenx just closed a billion-dollar deal with Janssen Pharmaceutica for their antibody cusatuzumab. Under the terms of the agreement, Janssen will pay arg…

Read more

How CRISPR/Cas9 is improving drug development using zebrafish

How CRISPR/Cas9 is improving drug development using zebrafish

CRISPR/Cas9 came to the attention of scientists everywhere over five years ago. Ever since it hit the main stage, the gene editing technique has stayed in the spotlight, and for good reason. CRISP…

Read more

Galapagos and MorphoSys to receive up to EUR 850mil in deal with Novartis

Galapagos and MorphoSys to receive up to EUR 850mil in deal with Novartis

Galapagos (Belgium) and MorphoSys (Germany) recently announced that they have entered into an exclusive global license agreement with Novartis. The Swiss big-pharma partner has acquired the rights…

Read more

Curing hay fever - ASIT Biotech allergy vaccines

Curing hay fever - ASIT Biotech allergy vaccines

The sun is shining, the grass is green, but hay fever season is at its peak! Many people (myself included) will spend a lot of money on antihistamines and tissues this summer. Wouldn’t it be lovel…

Read more

Stem cell patch restores vision to the blind

Stem cell patch restores vision to the blind

A stem cell patch has successfully restored sight to two blind patients in the UK. The Phase I trial is the first of its kind to use a whole engineered piece of tissue to treat vision impairment. …

Read more

Fishing for answers: screening drug cardiotoxicity using zebrafish

Fishing for answers: screening drug cardiotoxicity using zebrafish

Rodents have a well-established place in history as our most common animal models. Even the word lab-rat has become so commonplace it is a common lay-man term. However, could it be that another an…

Read more

UCB psoriasis drug approved for use in mothers

UCB psoriasis drug approved for use in mothers

The UCB core drug CIMZIA® has just been approved by European Medicines Agency (EMA) for use in pregnant and breastfeeding mothers. The company has also sought to have CIMZIA approved for psoriasis…

Read more

The Cystic Fibrosis association pushes research to the next level

The Cystic Fibrosis association pushes research to the next level

Cystic fibrosis (CF) is a life-threatening disease, for which there is currently no treatment. There are some drugs on the market that, in certain cases, can alleviate the symptoms. In this articl…

Read more

AI improves patient care

AI improves patient care

Curing and caring for patients is a comprehensive process that requires research to discover new drugs, clinical trials to test the safety and efficacy of those drugs, and coaching and mentoring t…

Read more

Partnering for a better mental health

Partnering for a better mental health

To address the challenges of drug development, solid strategic partnerships are needed. On the Janssen partner day, the company showcased an ongoing partnership with the University of Antwerp in m…

Read more

Biowin presents the SMART project

Biowin presents the SMART project

The company CluePoints provides software that is able to analyse, compare and measure huge amounts of data for clinical trials, with the aim of detecting anomalies. CluePoints is an outgrowth of t…

Read more

VC Views

Bringing clinical trials into the home

Bringing clinical trials into the home

Lowering the costs of drug development is more important than ever; with the increasing pressure on drug pricing and billions in funding poured into small biotechs, competition is fierce. While th…

Read more

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

KU Leuven Itera Life Science Biowin Flanders.bio UGent GSK Janssen Turnstone V-Bio Ventures XpandInnovation

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.